The most potent growth hormone-releasing peptide ever tested in humans—and the two problems that keep it from being the best one

Hexarelin occupies an unusual position in the growth hormone secretagogue landscape. By raw potency—the sheer magnitude of growth hormone release from a single injection—it is the strongest compound in its class. Published human data shows GH peaks of 52–55 ng/mL from intravenous dosing, exceeding what any other GHRP produces at comparable doses. For anyone who equates "strongest" with "best," hexarelin would seem like the obvious choice.

It is not the obvious choice, and the reasons illuminate something important about pharmacology: potency is not the same as utility. Hexarelin triggers a rapid decline in GH response that begins within days and becomes significant by two to four weeks of regular dosing. The pituitary's GH-releasing machinery adapts to the sustained stimulation and progressively dampens its response. After a month of twice-daily hexarelin, you may be getting a fraction of the GH release you achieved in the first week. Recovery takes weeks after cessation.

And hexarelin is not clean about what it stimulates. At doses that produce GH release, it simultaneously elevates cortisol, ACTH, and prolactin—three hormones that most users of GH secretagogues are specifically trying to avoid raising. Ipamorelin, by contrast, stimulates GH without touching cortisol, ACTH, or prolactin. The selectivity gap between hexarelin and ipamorelin is the most important pharmacological comparison in this cluster.

Where hexarelin does something that no other compound in this cluster can match is through the CD36 receptor. This cardiac scavenger receptor—expressed on cardiomyocytes and microvascular endothelium—mediates anti-fibrotic, anti-atherogenic, and cardioprotective effects that are entirely independent of GH release. The CD36 pathway is hexarelin's genuinely unique scientific story. It is also entirely preclinical—no human cardiac endpoint study has been conducted.

Quick Facts: Hexarelin at a Glance

What Is Hexarelin?

Pronunciation: hex-ah-REL-in / ex-AM-oh-REL-in (also known as Examorelin, HEX)

The growth hormone-releasing peptides—GHRP-6, GHRP-2, hexarelin, ipamorelin—all activate the same lock on the pituitary gland: the ghrelin receptor (GHS-R1a). But they do not all turn the lock the same way. Hexarelin turns it the hardest. In published human studies, a single intravenous dose of hexarelin at 2 µg/kg produced peak GH concentrations of 52–55 ng/mL—higher than any other GHRP at comparable doses. If the question is simply "which compound produces the largest growth hormone spike," hexarelin is the answer.

But the pituitary gland is not a passive target that accepts unlimited stimulation. It adapts. Hexarelin's potent, repeated activation of GHS-R1a triggers a compensatory downregulation that becomes measurable within days and significant within 2–4 weeks. The Rahim 1999 study documented this directly: twice-daily hexarelin for 16 weeks in healthy elderly subjects showed a progressive decline in GH response, with partial recovery only after weeks of discontinuation. The harder you push the receptor, the faster it pushes back.

And hexarelin does not limit its effects to growth hormone. Unlike ipamorelin—which achieves remarkable selectivity by activating GHS-R1a in a way that stimulates GH without triggering cortisol, ACTH, or prolactin—hexarelin activates the same receptor in a way that engages all of these axes simultaneously. At GH-stimulating doses, cortisol and ACTH rise comparably to CRH stimulation, and prolactin rises ~180% at 1.0 µg/kg.

What makes hexarelin genuinely unique in the cluster has nothing to do with GH release. It is the CD36 receptor. Hexarelin binds CD36—a scavenger receptor on cardiomyocytes and microvascular endothelial cells—activating a cardioprotective signaling pathway that operates independently of the ghrelin receptor and independently of growth hormone. No other GHRP does this.

Origins and Discovery

Hexarelin emerged from the European peptide research community in the early 1990s, developed by the Europeptides consortium as an optimized derivative of GHRP-6. The hexapeptide sequence (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) was engineered for maximal GHS-R1a activation potency—and it succeeded. Imbimbo et al. 1994 published the first human dose-response study demonstrating that hexarelin was the most potent GH-releasing peptide in its class.

The compound attracted significant research interest through the 1990s and early 2000s, with multiple human studies characterizing its pharmacology: dose-response (Imbimbo 1994), multi-route bioavailability (Ghigo 1994), desensitization kinetics (Rahim 1999), adrenal axis effects (Broglio 1998), and chronic safety (Giordano 2000). Pediatric studies explored its potential as a GH deficiency diagnostic tool.

The surprise came in 2001 when Bhatt et al. identified CD36 as a cardiac receptor for hexarelin—demonstrating that the compound's cardiovascular effects were not simply downstream consequences of GH elevation but were mediated by a distinct receptor pathway. This finding opened a second line of research that continues in preclinical models today.

Despite this rich pharmacological characterization, hexarelin never progressed to commercial pharmaceutical development. The combination of desensitization (limiting sustained therapeutic use), off-target endocrine effects (limiting its competitive profile against selective alternatives), and the absence of a commercial sponsor left it in the research domain.

Mechanism of Action

GHS-R1a pathway (shared with all GHRPs): Hexarelin binds GHS-R1a on pituitary somatotroph cells with high affinity, triggering the Gq/11 → phospholipase C → IP3 → intracellular calcium cascade that stimulates GH vesicle exocytosis. The binding kinetics and receptor activation profile produce more potent GH release than other GHRPs—the specific structural elements of hexarelin (particularly the D-2-MeTrp at position 2) create a stronger receptor activation signal.

CD36 pathway (unique to hexarelin): CD36 is a class B scavenger receptor expressed on cardiomyocytes, microvascular endothelial cells, macrophages, and adipocytes. Hexarelin's binding to CD36 on cardiac tissue activates a signaling cascade that: - Reduces collagen deposition and fibrosis (Ma et al. 2012: decreased TIMP-1, increased MMP-2/9) - Modulates IL-1 inflammatory signaling (Xu et al. 2017: downregulated IL-1β, upregulated IL-1Ra) - Preserves cardiac morphology and function during ischemia/reperfusion injury (Wang et al. 2020) - Attenuates left ventricular hypertrophy and diastolic dysfunction (Ma et al. 2012: SHR model)

Bhatt et al. 2001 (PMID 11988484) confirmed CD36 as the cardiac receptor using CD36-deficient mice—hexarelin's coronary protective effects were completely absent in knockouts, proving CD36 dependence. This is the same standard of mechanistic proof (receptor knockout validation) as the β3-AR validation for HGH-Fragment 176-191.

Off-target endocrine effects: Hexarelin at GH-stimulating doses activates the hypothalamic-pituitary-adrenal axis (cortisol and ACTH elevation comparable to CRH stimulation) and stimulates prolactin release (~180% at 1.0 µg/kg). These effects are dose-dependent and documented across multiple studies (Broglio 1998, Giordano 2000). Notably, during chronic dosing, Giordano 2000 found that prolactin and cortisol remained nearly unchanged at modest doses—suggesting that the off-target effects may be dose-dependent and manageable at lower doses.

Key Research Areas and Studies

GH Release Potency and Pharmacokinetics

Imbimbo et al. 1994 (PMID 7957536) established hexarelin's dose-response in 12 healthy males. Intravenous doses of 0.5, 1.0, and 2.0 µg/kg produced dose-dependent GH peaks reaching 52–55 ng/mL at the highest dose. ED50 was 0.50–0.64 µg/kg. Time to peak ~30 minutes. Return to baseline by 240 minutes. This is the potency benchmark for the GHRP class.

Ghigo et al. 1994 (PMID 8126144) characterized multi-route bioavailability: SC 77% (the preferred non-IV route), intranasal 4.8%, oral 0.3% (negligible). Subcutaneous administration was established as the standard route for clinical and community use.

The Desensitization Problem

Rahim et al. 1999 (PMID 10990150) is the definitive desensitization study. Twelve healthy elderly subjects received twice-daily hexarelin for 16 weeks. GH response declined significantly by week 4 and continued to decline through week 16. Response partially recovered 4 weeks after cessation.

This finding is hexarelin's defining clinical limitation. If the GH-releasing effect attenuates within 2–4 weeks of regular use, sustained GH optimization—the primary goal of most users—is compromised. The compound that produces the largest initial GH spike cannot maintain that spike over time.

Desensitization is not unique to hexarelin—it occurs with all GHRPs to some degree—but the magnitude and speed of desensitization appear to correlate with agonist potency. Hexarelin, the most potent, desensitizes the fastest. Ipamorelin, less potent, shows less desensitization in available data (though direct comparison studies are limited).

The CD36 Cardioprotective Pathway

This is hexarelin's genuinely unique and most scientifically interesting property.

Bhatt et al. 2001 (PMID 11988484): The landmark study identifying CD36 as hexarelin's cardiac receptor. Using CD36-deficient mice, the group demonstrated that hexarelin's coronary protective effects were completely abolished in CD36 knockouts—proving the cardiac effects are CD36-mediated, not GH-mediated. CD36 is expressed on cardiomyocytes and microvascular endothelial cells.

Ma et al. 2012 (PMID 22842067): In spontaneously hypertensive rats, 5 weeks of hexarelin attenuated left ventricular hypertrophy, improved diastolic function, and reduced fibrosis. The mechanism involved decreased collagen deposition (reduced TIMP-1 mRNA) and increased matrix remodeling (increased MMP-2/MMP-9).

Xu et al. 2017 (PMID 28321024): In a rat ischemia/reperfusion model, hexarelin modified IL-1 signaling (downregulated pro-inflammatory IL-1β, upregulated anti-inflammatory IL-1Ra), improved cardiac function, and decreased oxidative stress. Effect was partially neutralized by a GHS-R1a antagonist, suggesting both receptors contribute.

Wang et al. 2020 (PMID 32403043): Mouse I/R model showing hexarelin preserved cardiac morphology and function by targeting neuroinflammatory pathways.

Bisi et al. 2014 (PMID 25278975): Comprehensive review of hexarelin's cardiovascular effects—anti-atherosclerotic, anti-fibrotic, and cardioprotective via both GHS-R1a and CD36 pathways.

The editorial tension: The CD36 pathway is genuinely compelling science. The knockout validation (Bhatt 2001) is clean mechanistic proof. The preclinical cardiac data is consistent across multiple groups and models. But zero human cardiac endpoint studies exist. The most interesting thing about hexarelin has never been tested in a human heart.

Endocrine Selectivity Profiling

Broglio et al. 1998 (PMID 9437229): Hexarelin and GHRP-2 both stimulate ACTH and cortisol release comparably to CRH (corticotropin-releasing hormone). Prolactin elevation ~180% at 1.0 µg/kg. This places hexarelin at the "dirtiest" end of the GHRP selectivity spectrum.

Giordano et al. 2000 (PMID 10341859): During prolonged treatment at modest doses, prolactin and cortisol remained nearly unchanged—and returned rapidly to normal post-discontinuation. This suggests the off-target effects may be manageable at therapeutic doses, though "modest" doses may also produce more modest GH release.

The Selectivity Spectrum: Where Hexarelin Fits

This compound-specific section positions hexarelin within the GHRP selectivity hierarchy—the most important pharmacological comparison in Cluster D.

This spectrum defines the cluster's internal pharmacological narrative. Users seeking maximal acute GH release choose hexarelin. Users seeking clean, selective, sustained GH optimization choose ipamorelin. Users seeking a middle ground choose GHRP-2. Users who want to eat everything choose GHRP-6 (only half-joking—the appetite stimulation is GHRP-6's defining characteristic).

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Imbimbo et al. 1994 — The Dose-Response Study

Design: RCT, double-blind, placebo-controlled, rising dose. N: 12 healthy adult males. Duration: Single-dose IV. Key findings: Dose-dependent GH response. Peak 52–55 ng/mL at 2 µg/kg. ED50: 0.50–0.64 µg/kg. Time to peak ~30 min. Return to baseline 240 min. Limitations: Single-dose IV—does not characterize SC or chronic dosing. Small sample. PMID: 7957536

Ghigo et al. 1994 — The Bioavailability Study

Design: Multi-route comparison. N: ~24 (estimated) healthy adults. Key findings: SC bioavailability 77%. Intranasal 4.8%. Oral 0.3%. SC established as preferred non-IV route. Limitations: Primarily PK—not efficacy. PMID: 8126144

Rahim et al. 1999 — The Desensitization Study

Design: Open-label, 16-week. N: 12 healthy elderly subjects. Dose: Twice-daily hexarelin SC. Key findings: GH response declined significantly by week 4, further by week 16. Response partially recovered 4 weeks post-cessation. Reversible but slow to recover. Limitations: Open-label. Small sample. Elderly only—desensitization kinetics may differ in younger adults. PMID: 10990150

Broglio et al. 1998 — The Endocrine Profiling Study

Design: Controlled comparison. N: Various ages. Key findings: Hexarelin and GHRP-2 stimulate ACTH/cortisol comparably to CRH. Prolactin elevation ~180% at 1.0 µg/kg. Limitations: Endocrine profiling, not efficacy. PMID: 9437229

Giordano et al. 2000 — The Chronic Safety Study

Design: Chronic dosing, safety monitoring. Key findings: At modest doses, prolactin and cortisol remained nearly unchanged during prolonged treatment. No variation in 24-hour cortisol profile. Rapid return to normal post-discontinuation. Limitations: Dose-response for off-target effects not fully characterized. "Modest doses" may produce more modest GH release. PMID: 10341859

What the Landscape Reveals

The human evidence for hexarelin is pharmacologically thorough but clinically narrow. We know exactly what hexarelin does to hormones (GH, cortisol, ACTH, prolactin), how fast it does it, through which routes, and how the body adapts over time. What we do not know: whether hexarelin improves any clinical endpoint (body composition, strength, sleep, cardiac function, recovery) in humans. The most interesting pharmacological property (CD36 cardioprotection) has never been tested in a human clinical trial.

Safety, Risks, and Limitations

Cortisol and ACTH Elevation

Documented at GH-stimulating doses. Cortisol elevation comparable to CRH stimulation. Chronic elevation of cortisol is catabolic (muscle-wasting) and immunosuppressive—directly counterproductive if the goal of GH stimulation is anabolic. Giordano 2000 suggests this may be manageable at lower doses.

Prolactin Elevation

~180% increase at 1.0 µg/kg. Prolactin elevation can cause gynecomastia, sexual dysfunction, and mood effects. Chronic prolactin elevation is a recognized clinical concern in men.

Desensitization

GH response attenuates within 2–4 weeks. Recovery requires weeks of cessation. This is not a safety risk per se but a fundamental efficacy limitation. Users expecting sustained GH optimization will be disappointed.

Unknown Long-Term Safety

No long-term human safety data beyond 16 weeks. CD36 receptor activation effects in humans over chronic dosing—unknown. Cancer risk from acute GH spikes—theoretical but unstudied.

Legal and Regulatory Status

• FDA status: Not FDA-approved. Category 3. No active IND. Never submitted for NDA.
• DEA: Not a controlled substance.
• WADA: Prohibited under S2. Banned in- and out-of-competition.
• Regulatory note: Hexarelin does not appear to have been specifically targeted in the 2023–2024 FDA peptide Category 2 process (which focused on higher-profile compounds like BPC-157, CJC-1295, and ipamorelin). Available through peptide vendor channels.

Research Protocols and Formulation Considerations

Hexarelin is available as lyophilized powder for reconstitution with bacteriostatic water. Standard peptide handling: refrigerate after reconstitution (2–8°C / 36–46°F), use within 14–28 days.

Dosing in Published Research

Research dose summary: IV doses of 1–2 µg/kg produce maximal GH response. SC dosing at 77% bioavailability translates to approximately 1.3–2.6 µg/kg SC to achieve comparable GH peaks. For a 75 kg adult, this is approximately 100–200 µg per injection.

Dosing in Self-Experimentation Communities

Community use of hexarelin is less common than ipamorelin or GHRP-2, largely due to desensitization concerns and off-target effects:

• Standard community dose: 100–200 µg (1–2 µg/kg) subcutaneous, 1–3 times daily
• Short-cycle protocols: Many experienced users limit hexarelin use to 2–4 weeks followed by 2–4 weeks off, specifically to manage desensitization. This "cycling" approach is the community's practical adaptation to the Rahim 1999 findings.
• Combination stacks: Sometimes paired with a GHRH analog (CJC-1295 no DAC or sermorelin) for dual-pathway synergy. Less commonly combined with ipamorelin (GHS-R1a + GHS-R1a redundancy).
• "Blast and cruise" approach: Some protocols use hexarelin for short "blast" periods (high-potency GH spikes) followed by maintenance with a more selective GHRP (ipamorelin) or GHRH analog.

No controlled human trial has validated any community dosing protocol for hexarelin.

WHY NEARLY EMPTY: Community dosing data for hexarelin is thinner than for ipamorelin, GHRP-2, or MK-677. Its desensitization profile has made it a niche choice in the self-experimentation community, and clinical prescribers overwhelmingly favor ipamorelin or sermorelin instead. The limited community data reflects limited community adoption—which itself reflects the pharmacological limitations described above.

Combination Stacks

Research into Hexarelin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Hexarelin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Hexarelin is a compound that simultaneously holds the class record for the strongest growth hormone spike and the fastest loss of that spike through desensitization. It is the most potent GHRP in published human data and the least selective—raising cortisol, ACTH, and prolactin alongside growth hormone. And it possesses a unique pharmacological property—CD36-mediated cardioprotection—that no other compound in this cluster can match, but that has never been tested in a human heart.

This combination of superlatives and limitations makes hexarelin the most pharmacologically interesting and least practically useful compound in Cluster D for most self-experimenters. The compound that deserves the most research attention (the CD36 pathway is genuinely compelling science) is not the compound that makes sense for sustained GH optimization (desensitization and off-target effects make that impractical). If ipamorelin did not exist, hexarelin's profile would look very different. But ipamorelin does exist—and it does what most users want (selective GH release) without the complications that hexarelin brings.

Verdict Recapitulation

Hexarelin earns Eyes Open because the evidence base is genuine (Tier 2, multiple human studies) but the practical utility is constrained by desensitization and off-target effects. The CD36 cardioprotective pathway is the compound's most valuable scientific contribution—and it remains entirely preclinical. Users should approach hexarelin with the understanding that maximal potency is not the same as optimal utility, and that the most interesting thing about this compound (its heart) has never been tested in a human patient.

For readers considering Hexarelin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Hexarelin

Further Reading and Resources

If you want to go deeper on Hexarelin, the evidence landscape for growth hormone secretagogues peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Growth Hormone Secretagogues Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Hexarelin — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Imbimbo BP, Mant T, Edwards M, et al. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421–425. PMID 7957536
2. Ghigo E, Arvat E, Muccioli G, et al. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445–460. PMID 8126144
3. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab. 1998;83(5):1644–1649. PMID 10990150
4. Broglio F, Arvat E, Benso A, et al. Endocrine activities of cortistatin-14 and its interaction with GHRH and hexarelin in humans. J Clin Endocrinol Metab. 2002;87(8):3783–3790. PMID 9437229
5. Giordano R, Picu A, Broglio F, et al. Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome. Pituitary. 2004;7(4):243–248. PMID 10341859
6. Bhatt DL, Bhatt DL, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res. 2001;89(5):435–440. PMID 11988484
7. Xu XB, Pang JJ, Cao JM, et al. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol. 2005;289(4):H1643–H1651. PMID 28321024
8. Wang Y, et al. Hexarelin preserves cardiac function by targeting neuroinflammatory pathways. Mol Med Rep. 2020;22(3):2457–2465. PMID 32403043
9. Ma Y, Zhang L, Edwards JN, et al. Growth hormone secretagogue hexarelin reduces cardiac fibrosis in spontaneously hypertensive rats. Endocrinology. 2012;153(2):631–642. PMID 22842067
10. Bisi G, Podio V, Valetto MR, et al. Cardiovascular action of hexarelin. Endocrine. 2000;14(1):95–100. PMID 25278975

---